2014, Number 2
PDF size: 515.78 Kb.
ABSTRACTPharmacological management of insulin resistance and dyslipidaemias in children and adolescents is required to prevent the development of metabolic syndrome (MS) and type II diabetes mellitus (DM2).
Material and method: we developed extemporaneous formulations from 500 mg-tablets from three generic brands, commercially available in Mexican drugstores: MedimartTM, Farmacias del AhorroTM and Primer NivelTM, dissolved in water sweetened with Splenda, which made them palatable and allowed customised dose adjustment. Solutions were stored at four environmental conditions: 25oC exposed to light, 25oC protected from light, 4oC and 40oC, and their physicochemical stability was assayed. The stability of the drug was determined by ultra performance liquid chromatography and ultraviolet detection (UPLC-UV) and by measuring the pH of the stock solution. The mobile phase consisted of (KH2PO4) 0.1 M, pH = 6.5, 4.6 mM sodium dodecyl sulphate (SDS) and acetonitrile (63:7:30) at 0.8 mL/min, column VARIAN Pursuit C8 150 × 3.9 mm tempered at 40oC, with detection at 236 nm.
Results: Metformin from all trademarks was stable at all storage conditions for up to 30 days, retaining more than 90% of the initial amount of active drug, with a pH of 7.4 ± 0.3.
Conclusion: Metformin extemporaneous formulations may be developed from either the innovator or generic brands, having the advantage of saving money and conserving the stability of its physicochemical properties.
Garnett SP, Baur LA, Noakes M, Steinbeck K, Woodhead HJ, Burrell S, Chisholm K, Broderick CR, Parker R, De S, Shrinivasan S, Hopley L, Hendrie G, Ambler GR, Kohn MR, Cowell CT. Researching Effective Strategies to Improve Insulin Sensitivity in Children and Teenagers - RESIST. A randomised control trial investigating the effects of two different diets on insulin sensitivity in young people with insulin resistance and/or pre-diabetes. BMC Public Health. 2010;10:575. doi: 10.1186/1471-2458-10-575
Ventura EE, Davis JN, Alexander KE, Shaibi GQ, Lee W, Byrd-Williams CE, Toledo-Corral CM, Lane CJ, Kelly LA, Weigensberg MJ, Goran MI. Dietary intake and the metabolic syndrome in overweight latino children. J Am Diet Assoc 2008;108:1355-9. doi: 10.1016/j.jada.2008.05.006.
Kanekara A, Sharma M. Pharmacological Approaches for Management of Child and Adolescent Obesity. J Clin Med Res 2010;2:105-11. doi: 10.4021/jocmr2010.05.288w
Lalau JD, Lacroix C, Compagnon P. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995;18:779-84.
Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574- 9.
Hermann LS, Scherstein B, Bitzen PO. Therapeutic comparison of metformin and sulfonylurea, alone, and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9.
Fulgencio JP, Kohl C, Girard J, Pégorier JP. Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochem Pharmacol 2001;62:439-46.
Alemón-Medina R, Coria-Jiménez R, Ramírez-Mendiola B, Rivera-Espinosa L, García-Álvarez R, Juárez-Olguín H, Chávez-Pacheco JL. Physicochemical and microbiological stabilities of a sweetened and calorie-free metformin extemporaneous formulation for pediatrics. Lat Am J Pharm 2012;31:1253-60.
PROYECTO-NOM-177-SSA1-2013. Proyecto de Norma Oficial Mexicana-177-SSA1-2013. Diario Oficial de la Federación. 2013.
Kendall DL, Amin R, Clayton PR. Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes. Pediatr Drugs 2014;16:13-20.
Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int J Obes 2011;35:891-8.
Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centripetal obesity, insulin, leptin and low density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with BMI>30. Metabolism 2011;50:856–61.
Díaz de León-Castañeda C, Altagracia-Martínez M, Kravzov- Jinich J, Cárdenas-Elizalde MR, Moreno-Bonett C, Martínez- Núñez JM. Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. Clinicoecon Outcomes Res 2012;4:57–65. doi: 10.2147/CEOR. S27826
Juárez-Olguín H. Uso de formulas magistrales en pediatría. Acta Pediátrica de México. 2011;32:175-176.
Chávez-Pacheco JL, Rivera-Espinosa L, Alemón-Medina R, González-Zamora JF, Ramírez-Mendiola B, Flores-Pérez J, Juárez-Olguín H, Flores-Pérez C. Development and sedative effect of a new formulation of midazolam in chocolate bars. Lat Am J Pharm 2011;30:1977-84.
Nunn AJ. 2003. Making medicines that children can take. Arch Dis Child 2003;88:369-71.
Schirm E, Tobi H, De Jong-van den Berg LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003;111:291-5.
Strickley RG, Iwata Q, Wu S, Dahl TC. Pediatric Drugs -A Review of Commercially Available. Journal of Pharmaceutical Sciences 2008;97:1731- 1774.
Young DA, Bowen WH. 1990. The influence of sucralose on bacterial metabolism. J Dent Res 1990;69:1480-4.